

IGF-II

Catalog # PVGS1339

Product Information

Primary Accession P01344-1 **Species** Human

Sequence Ala25-Glu91, expressed with an N-terminal Met

> 95% as analyzed by SDS-PAGE **Purity**

> 95% as analyzed by HPLC

Endotoxin Level

Expression System E. coli

Formulation Lyophilized after extensive dialysis against 25 mM Tris, pH 8.0.

Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to

bring the contents to the bottom. Reconstitute the lyophilized powder in

 ddH_2O up to 100 $\Box g/ml$.

Upon receiving, this product remains stable for up to 6 months at lower than Storage & Stability

> -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw

cycles.

Additional Information

Target Background

Insulin-like Growth Factor II (IGF-II) is a single chain 7 kDa polypeptide, and shares a high degree of homology with insulin. During circulation in vivo, IGF-II is complexed to high affinity binding proteins, IGF Binding Proteins (IGFBP), which act as circulating reservoirs, transport IGF-II, and prolong the half life of IGF-II. The receptors of IGF-II (IGFRs) are transmembrane tyrosine receptors, and are heterotetrameric consisting of two α-subunits and two β-subunits. IGFRs execute their role via intracellullar signaling molecules, such as IRS, shc, and PI3K. The functions of IGF-II include promoting cell survival, growth, proliferation, differentiation and motility. In particular, IGF-II promotes proliferation, inhibits death, and stimulates transformation in

breast cancer cells.

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.